1 Cardiovascular and metabolic responses to intravenous infusion of isoprenaline were measured in fasted, anaesthetized cats. 2 Isoprenaline (0.2 jg kg-' min-' for 15 min) decreased diastolic blood pressure and increased heart rate, blood glucose, blood lactate and plasma free fatty acids. 3 Oxprenolol (0.5 mg/kg) antagonized all cardiovascular and metabolic effects of isoprenaline nonselectively. 4 Para-oxprenolol (0.25 mg/kg) and practolol (4 mg/kg) antagonized the effects of isoprenaline on heart rate and free fatty acids selectively.
Introduction
It has been proposed that /3-adrenoceptors mediating pharmacological responses to sympathomimetic agonists are differentiated into two subtypes designated 'P,' and 'f2' (Lands, Arnold, McAuliff, Luduena & Brown, 1967 ). This classification is based on the relatively selective activity of certain agonists in producing these responses. Thus, adrenoceptors on which noradrenaline has strong activity, such as those mediating cardiostimulation, have been assigned to the /, subtype. Conversely, adrenoceptors on which noradrenaline has weak activity, including those mediating vasodilatation and bronchodilatation, have been assigned to the 42 subtype. For each response, the activity of noradrenaline has been assessed in comparison with that of other agonists, primarily adrenaline and isoprenaline, which appear to have strong activity on both the , and 62 subtypes of adrenoceptor.
The selective agonist activity of noradrenaline has also been used to classify /B-adrenoceptors mediating metabolic responses. Thus, due to the strong activity of noradrenaline on lipolytic adrenoceptors mediating release of free fatty acids (FFA), these adrenoceptors have been assigned to the f, subtype (Lands et al., 1967) . Conversely, liver and muscle glycogenolytic adrenoceptors mediating release of glucose and lactate, respectively, have been assigned to the f2 category due to the relatively weak activity of noradrenaline in producing these responses (Arnold, McAuliff, O'Connor & Brown, 1968) .
Metabolic responses to adrenaline and isoprenaline have also been compared with those produced by selective non-catecholamine agonists. Tazolol, or ITP, selectively produces cardiostimulation (Strosberg & Roszkowski, 1972) ; this agonist increases plasma FFA but does not increase glucose or lactate (Lockwood & Lum, 1974) . Tazolol is therefore a presumably P, selective agonist which supports the Lands' classification of,i-adrenoceptors. However, the actions of presumably P2 selective agonists are less consistent with this classification. Thus, salbutamol selectively produces bronchodilatation (Cullum, Farmer, Jack & Levy, 1969) yet this agonist is more active in producing increases in plasma FFA and less active in producing increases in blood lactate (Kelly & Shanks, 1975) than would be expected in a selective 2 agonist.
In the present study, an attempt has been made to provide evidence regarding differentiation of metabolic adrenoceptors by the use of P-adrenoceptor antagonists which are presumed to be non-selective or selective for either cardiac or vascular /i-adrenoceptors. Cardiovascular and metabolic responses to intravenous infusion of isoprenaline have been measured in control animals. These responses have been compared to those observed in animals pretreated with practolol, an antagonist which selectively blocks isoprenaline-induced cardiostimulation (Dunlop & Shanks, 1968) and with H 35/25, an antagonist which selectively blocks isoprenaline-induced vasodilatation (Levy & Wilkenfeld, 1969 Arterial blood glucose levels were determined by the o-toluidine method of Dubowski (1962) . Arterial blood lactate levels were determined by the lactate dehydrogenase method of Marbach & Weil (1967) .
Arterial plasma FFA were measured by the copper complexation method of Duncombe (1964) .
The following drugs were used: (±)-isoprenaline hydrochloride (Winthrop Laboratories, Inc.), oxprenolol hydrochloride (Ciba-Geigy, Ltd.), paraoxprenolol hydrochloride (Ciba-Geigy, Ltd.), practolol (Imperial Chemical Industries, Ltd.) and H 35/25 (1-(4-methylphenyl)-2-isopropyl aminopropanol) hydrochloride, Axel Kistner AB). 
Cardiovascular responses to isoprenaline
Heart rate and diastolic BP were recorded just before (time 0) and at 5, 10 and 15 min after beginning isoprenaline infusion. Isoprenaline significantly increased heart rate and decreased diastolic blood pressure; these effects persisted throughout the period of infusion but were maximal at 5 min after beginning isoprenaline administration (Table 1) .
Metabolic responses to isoprenaline
Blood glucose, blood lactate and plasma FFA levels were determined in samples taken just before (time 0) and at 5, 10 and 15 min after beginning isoprenaline infusion. Isoprenaline significantly increased glucose, lactate and FFA levels; these effects were progressive throughout the period of infusion and therefore were maximal at 15 min after beginning isoprenaline administration (Table 1) .
Cardiovascular and metabolic responses to 8-adrenoceptor antagonists
Cardiovascular and metabolic parameters were measured just before and at 15 min after administration of oxprenolol, para-oxprenolol, practolol or H 35/25. The doses of antagonists used were those found to produce significant antagonism of at least one of the cardiovascular responses to isoprenaline infusion. Oxprenolol, para-oxprenolol and practolol produced small but significant increases in blood glucose ( Table 2 ). As shown in Table 2 , paraoxprenolol was the only antagonist which produced significant changes in diastolic blood pressure, blood lactate and plasma FFA while oxprenolol was the only antagonist which produced a significant change in heart rate.
Effect of antagonists on cardiovascular responses to isoprenaline Heart rate and diastolic BP were recorded at time 0, which was 15 min after administration of antagonists and just before beginning isoprenaline, and at 5, 10 and 15 min after beginning isoprenaline infusion. Maximal changes in heart rate and diastolic BP produced by isoprenaline in animals pretreated with antagonists were compared with maximal changes produced in non-pretreated controls (Table 3) . Oxprenolol non-selectively antagonized both the increase in heart rate and the decrease in blood pressure produced by isoprenaline in controls. In contrast to this, para-oxprenolol and practolol selectively antagonized the isoprenaline-induced increase in heart rate while H 35/25 selectively (Table 3) . Oxprenolol non-selectively antagonized all metabolic responses to isoprenaline. In contrast to this, para-oxprenolol and practolol selectively antagonized the isoprenaline-induced increase in plasma FFA while H 35/25 selectively antagonized the isoprenaline-induced increases in blood glucose and blood lactate.
Discussion
The metabolic adrenoceptors mediating isoprenalineinduced increases in blood glucose, blood lactate and plasma FFA appear to consist exclusively of fiadrenoceptors. Accordingly, it has been established that these metabolic responses to isoprenaline can be completely blocked by the /3-adrenoceptor antagonist, propranolol (Barrett & Cullum, 1968) . Unlike isoprenaline, other sympathomimetic agonists such as adrenaline are associated with an a-adrenoceptormediated inhibition of pancreatic insulin release which presumably contributes to the increase in blood glucose produced by these agonists (Altszuler, Gottlieb, Steel & Bjerknes, 1974) . Although the increase in blood glucose produced by isoprenaline appears to be due primarily to stimulation of liver glycogenolysis, it is possible that this response is enhanced by simultaneous stimulation of muscle glycogenolysis. This is consistent with the observation that elevation of blood lactate (by i.v. infusion of sodium lactate) significantly increases blood glucose (Miller, Issekutz, Paul & Rodahl, 1964) . This is probably due to the increased availability of lactate for liver gluconeogenesis. On the other hand, elevation of blood lactate or glucose may diminish increases in plasma FFA due to stimulation of lipolytic adrenoceptors by facilitating re-esterification to triglycerides (Miller et al., 1964 (Hardman & Mayer, 1965) . Furthermore, neuronal uptake inactivation does not explain the relatively strong activity of noradrenaline compared to other catecholamines in producing increases in plasma FFA (Barrett, 1965 (Cash, Woodfield & Allan, 1970) and therefore blockade of the 'cardiac' padrenoceptor subtype is problematical. Butoxamine, an antagonist which selectively antagonizes isoprenaline-induced vasodilatation (Parratt & Wadsworth, 1970) , also antagonizes isoprenalineinduced increases in glucose and lactate (Salvadore, April & Lemberger, 1966) . However, butoxamine has also been reported to block increases in plasma FFA produced by sympathomimetic agonists (Colville, Lindsay & Burns, 1965) 
